Report

Brighter - Waiting on the CE mark

Back in December, Brighter announced that all the technical documentation had been submitted to the designated notified body for final approval of a CE mark for the Actiste device. We expect a decision around the end of H119. Initial commercialisation is expected to focus on Gulf Cooperation Council (GCC) countries, especially the United Arab Emirates (UAE). In the interim, management has been working on additional capital injections, including SEK17.5m in Q1 and an additional SEK19.6m after the end of the quarter.
Underlying
Brighter AB

Brighter publ AB is a Sweden-based company active in the healthcare sector. It is primarily engaged in the development of Brighter One, a self-care device dedicated for type 1 and type 2 diabetes patients. Brighter One integrates a lancet, blood glucose meter for test strips, dosing and injection mechanism, and storage of glucose level and dosing history data. The Company cooperates with partners such as Almi Foretagspartner AB and Innovationsbron, as well as a distributor Rubin Medical.

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Analysts
Maxim Jacobs

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch